A low dose (6.5 mg) of intravaginal DHEA permits a local action while maintaining serum estrogens or androgens as well as their metabolites within normal values.
Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has expanded its original agreement with Endoceutics to commercialise Intrarosa® (prasterone) in Australia.
